210 related articles for article (PubMed ID: 17224859)
1. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women.
Grady D; Vittinghoff E; Lin F; Hanes V; Ensrud K; Habel LA; Wallace R; Macer J; Cummings SR; Shepherd J
Menopause; 2007; 14(3 Pt 1):391-6. PubMed ID: 17224859
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
3. Effects of ultra-low-dose transdermal estradiol on cognition and health-related quality of life.
Yaffe K; Vittinghoff E; Ensrud KE; Johnson KC; Diem S; Hanes V; Grady D
Arch Neurol; 2006 Jul; 63(7):945-50. PubMed ID: 16831962
[TBL] [Abstract][Full Text] [Related]
4. Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene.
Nielsen M; Raundahl J; Pettersen PC; Loog M; Karemore G; Karsdal MA; Christiansen C
Menopause; 2009; 16(4):785-91. PubMed ID: 19322115
[TBL] [Abstract][Full Text] [Related]
5. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density.
Lundström E; Bygdeson M; Svane G; Azavedo E; von Schoultz B
Climacteric; 2007 Jun; 10(3):249-56. PubMed ID: 17487652
[TBL] [Abstract][Full Text] [Related]
6. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial.
Ettinger B; Ensrud KE; Wallace R; Johnson KC; Cummings SR; Yankov V; Vittinghoff E; Grady D
Obstet Gynecol; 2004 Sep; 104(3):443-51. PubMed ID: 15339752
[TBL] [Abstract][Full Text] [Related]
7. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
Bunyavejchevin S; Limpaphayom KK
J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
[TBL] [Abstract][Full Text] [Related]
8. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
[TBL] [Abstract][Full Text] [Related]
9. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
10. A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
Cigler T; Tu D; Yaffe MJ; Findlay B; Verma S; Johnston D; Richardson H; Hu H; Qi S; Goss PE
Breast Cancer Res Treat; 2010 Apr; 120(2):427-35. PubMed ID: 19967558
[TBL] [Abstract][Full Text] [Related]
11. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.
Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E
Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and breast density changes.
Harvey J; Scheurer C; Kawakami FT; Quebe-Fehling E; de Palacios PI; Ragavan VV
Climacteric; 2005 Jun; 8(2):185-92. PubMed ID: 16096175
[TBL] [Abstract][Full Text] [Related]
15. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
16. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
Arrenbrecht S; Boermans AJ
Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
[TBL] [Abstract][Full Text] [Related]
17. Association of new-onset breast discomfort with an increase in mammographic density during hormone therapy.
Crandall CJ; Karlamangla A; Huang MH; Ursin G; Guan M; Greendale GA
Arch Intern Med; 2006 Aug 14-28; 166(15):1578-84. PubMed ID: 16908790
[TBL] [Abstract][Full Text] [Related]
18. The effect of low dose hormone therapy on mammographic breast density.
Christodoulakos GE; Lambrinoudaki IV; Vourtsi AD; Vlachou S; Creatsa M; Panoulis KP; Botsis D
Maturitas; 2006 Apr; 54(1):78-85. PubMed ID: 16198519
[TBL] [Abstract][Full Text] [Related]
19. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
Samsioe G; Hruska J;
Climacteric; 2010 Feb; 13(1):34-44. PubMed ID: 20001563
[TBL] [Abstract][Full Text] [Related]
20. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
